î
îŒ
î
Clearmind Medicine Inc
CMNDî¹
詳现ãã£ãŒãã衚瀺
2.740USD
+0.130+4.98%
çµå€Â 12/19, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
14.74Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+4.98%
5æ¥é
+3587.75%
1ã¶æ
+1253.09%
6ã¶æ
+218.60%
幎åæ¥
+98.55%
1幎é
+130.25%
詳现ãã£ãŒãã衚瀺
TradingKeyã®Clearmind Medicine Incã®æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2025-10-27äž»èŠã€ã³ãµã€ã
ããªã¥ãšãŒã·ã§ã³ã¯å²å®ãšè©äŸ¡ãããŠããŸããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Clearmind Medicine Incã®ã¹ã³ã¢î°î°
æ¯æç·ãšæµæç·
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¢ããªã¹ãç®æšæ ªäŸ¡
0
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
--
çŸåšã®è©äŸ¡
0.000
ç®æšæ ªäŸ¡
0.00%
äžæäœå°
å
責äºé
ïŒã¢ããªã¹ãã®ã¬ãŒãã£ã³ã°ããã³ç®æšæ ªäŸ¡ã¯ãæ
å ±æäŸã®ã¿ãç®çãšããŠLSEG Data & AnalyticsãæäŸãããã®ã§ãããæè³å©èšãæ§æãããã®ã§ã¯ãããŸããã
Clearmind Medicine Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Companyâs intellectual portfolio consists of 19 patent families including 31 granted patents.
å²å®
å瀟ã®ææ°ã®PEã¯-1.32ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠå®å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯589.42Kæ ªã§ãåååææ¯ã§42.22%æžå°ããŠããŸãã
ãžã§ãšã«ã»ã°ãªãŒã³ãã©ãããä¿æ
ã¹ã¿ãŒæè³å®¶ãžã§ãšã«ã»ã°ãªãŒã³ãã©ããã¯æ¬éæã344.52Kæ ªä¿æããŠããŸãã
Clearmind Medicine Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Clearmind Medicine Incã®äŒæ¥æ å ±î
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Companyâs intellectual portfolio consists of 19 patent families including 31 granted patents.
äŒæ¥ã³ãŒãCMND
äŒæ¥åClearmind Medicine Inc
æé«çµå¶è²¬ä»»è
ãCEOãZuloff-Shani (Adi)
ãŠã§ããµã€ãhttps://www.clearmindmedicine.com/
ãããã質å
Clearmind Medicine IncïŒCMNDïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îClearmind Medicine IncïŒCMNDïŒã®çŸåšã®æ ªäŸ¡ã¯2.740ã§ãã
Clearmind Medicine Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îClearmind Medicine Incã®ãã£ãã«ãŒã·ã³ãã«ã¯CMNDã§ãã
Clearmind Medicine Incã®52é±é«å€ã¯ãããã§ããïŒ
îClearmind Medicine Incã®52é±é«å€ã¯87.200ã§ãã
Clearmind Medicine Incã®52é±å®å€ã¯ãããã§ããïŒ
îClearmind Medicine Incã®52é±å®å€ã¯2.360ã§ãã
Clearmind Medicine Incã®æ䟡ç·é¡ã¯ãããã§ããïŒ
îClearmind Medicine Incã®æ䟡ç·é¡ã¯14.74Mã§ãã
Clearmind Medicine Incã®çŽå©çã¯ãããã§ããïŒ
îClearmind Medicine Incã®çŽå©çã¯-5.25Mã§ãã
Clearmind Medicine Inc (CMND) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãClearmind Medicine IncïŒCMNDïŒã®ç·åè©äŸ¡ã¯--ã§ãç®æšæ ªäŸ¡ã¯--ã§ãã
Clearmind Medicine Inc (CMND) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îClearmind Medicine IncïŒCMNDïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.759ã§ãã
é¢é£éèåå
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%人æ°éæ
